Struggling to find a reliable GLP-1 manufacturer in India? You’re not alone. With the recent boom in GLP-1 demand, navigating the sea of suppliers can be overwhelming—how do you know which factories deliver quality, consistency, and the compliance you need? Choosing the right manufacturer isn’t just about price. It’s about building a partnership that supports your product goals and business success for the long run. Curious which Indian factories stand out from the rest?
Dive into our comparison guide and discover your best GLP-1 manufacturing match!
Related Video
Indian Pharmaceutical Companies: GLP-1 Drug Manufacturing
Product Details:
GLP-1 drugs (glucagon-like peptide-1 agonists) manufactured by Indian pharmaceutical companies, intended mainly as generic versions following the anticipated 2026 expiry of Novo Nordisk’s semaglutide patent. Key players include Biocon, Sun Pharma, Cipla, Dr. Reddy’s, and Lupin.
Technical Parameters:
– GLP-1 agonists regulate blood sugar by slowing digestion and increasing satiety.
– Typically administered as injectable medications.
– Primary active ingredient: semaglutide (post-patent expiration).
– Development and production aligned with India’s upcoming Production-Linked
Application Scenarios:
– Treatment of type 2 diabetes in adult patients.
– Aiding weight loss and treating obesity, pending regulatory approval for this
– Improving access to affordable GLP-1 drugs for Indian patients post-patent
– Potential for export to global markets as low-cost GLP-1 generics.
Pros:
– Expected reduction in drug prices due to competition and generic manufacturing.
– Improved accessibility for diabetes and obesity treatments in India.
– Government-backed incentives (PLI scheme) may foster innovation and domestic
– Ability for multiple leading pharmaceutical companies to produce and distribute.
Cons:
– Market entry and sales for obesity applications subject to regulatory approval.
– Production incentives are contingent on manufacturing post-2026 patent
– Success depends on the ability of companies to scale and meet demand
India to make Ozempic-like drugs for diabetes, obesity under PLI by …
Product Details:
Indian pharmaceutical companies will manufacture GLP-1 receptor agonist (GLP-1RA) peptide drugs, similar to Ozempic and Mounjaro, for diabetes and obesity treatment under the Production Linked Incentive (PLI) scheme, commencing around 2026 when relevant patents expire.
Technical Parameters:
– GLP-1RA drugs function by activating GLP-1 receptors in the pancreas, enhancing
– Demonstrated effects include lowering glycaemic parameters and promoting weight
– Classified as peptide drugs.
Application Scenarios:
– Treatment of type 2 diabetes.
– Management of obesity.
– Potential off-label use for weight loss.
Pros:
– Promotes both improved blood glucose control and clinically significant weight
– Will be manufactured in India, increasing local accessibility and potentially
– Supports India’s pharmaceutical innovation and competitiveness under the PLI
Cons:
– Current global supply is constrained, leading to shortages and circulation of
– Off-label usage is rising, potentially risking misuse or overconsumption.
Glenmark is the first to launch Biosimilar of Popular Anti-Diabetic …
Product Details:
Glenmark has launched the biosimilar of Liraglutide, a popular anti-diabetic drug, in India under the brand name Lirafit. It is the first company in India to launch this biosimilar for the treatment of Type 2 diabetes mellitus.
Technical Parameters:
– Biosimilar to Liraglutide (reference Victoza® by Novo Nordisk)
– Administered via injection (pre-filled pens)
– Available in multiple strengths (commonly 6 mg/ml concentration in 3 ml
– Intended for use as adjunct to diet and exercise in adults with Type 2 diabetes
Application Scenarios:
– Management of Type 2 diabetes mellitus in adult patients
– Patients requiring injectable therapy for blood glucose control
– Use as adjunct to existing oral anti-diabetic medications and lifestyle
Pros:
– First biosimilar of Liraglutide launched in India, potentially increasing
– Enables advanced diabetes care options for Indian patients
– May offer an affordable alternative to the original branded product
Cons:
– Potential skepticism around efficacy or safety compared to the original branded
– Limited initial real-world clinical experience in the Indian population
Novo Nordisk India launches world’s first and only GLP-1 RA, Oral …
Product Details:
Novo Nordisk India has launched Rybelsus®, the world’s first and only oral GLP-1 receptor agonist, containing the active ingredient semaglutide, designed for the management of type 2 diabetes.
Technical Parameters:
– Active ingredient: oral semaglutide (GLP-1 receptor agonist)
– First and only oral form of GLP-1 RA, previously only available as injectable
– Once-daily oral tablet formulation
Application Scenarios:
– Management of adults with type 2 diabetes
– Patients requiring GLP-1 RA therapy who prefer an oral alternative to injections
– Improving glycaemic control alongside diet and exercise
Pros:
– Oral formulation offers increased convenience and improved patient compliance
– Proven to lower blood sugar (HbA1c) and support weight loss in type 2 diabetes
– Provides a novel treatment option in the Indian diabetes therapy landscape
Cons:
– As a new oral medication, some patients may experience gastrointestinal side
– Long-term safety and effect compared to established injectables may still
Eli Lilly launches once-a-week diabetes drug in India
Product Details:
Eli Lilly has launched a once-a-week diabetes drug in India.
Technical Parameters:
– Once-weekly dosage
– Designed for patients with type 2 diabetes
– Administered via injection
Application Scenarios:
– Management of type 2 diabetes
– Patients requiring less frequent dosing for diabetes control
Pros:
– Reduced frequency of injections compared to daily treatment
– Potential for improved patient compliance
Cons:
– Requires injection (not oral)
– Specific efficacy and safety profile details not provided
India To Manufacture Popular Diabetes And Obesity Drugs From 2026 Under …
Product Details:
India will begin manufacturing popular diabetes and obesity drugs domestically starting from 2026 under the Production Linked Incentive (PLI) Scheme. These are widely used pharmaceuticals aimed at managing diabetes and obesity.
Application Scenarios:
– Treatment and management of diabetes in patients
– Treatment and management of obesity in patients
Pros:
– Domestic manufacturing may lead to improved self-reliance in critical
– Potential reduction in drug costs due to local production
– Enhanced accessibility of essential diabetes and obesity medications in India
Cons:
– Manufacturing is scheduled to begin only in 2026, causing potential delays in
– Specific technical standards, clinical performance, or efficacy details of the
GLP-1 Therapies Transforming Obesity Treatment in India
Product Details:
GLP-1 receptor agonists (including semaglutide, liraglutide, and upcoming generics/tirzepatide), developed primarily for diabetes but now used for obesity management. Offered by companies such as Novo Nordisk (Rybelsus, Ozempic, Wegovy), Biocon, Cipla, Dr. Reddy’s, Glenmark, Sun Pharma, and Eli Lilly (Mounjaro).
Technical Parameters:
– Mimic the incretin hormone GLP-1 to enhance insulin secretion, suppress
– Demonstrated up to 15% body weight loss over 68 weeks (semaglutide in clinical
– Available as oral (e.g., Rybelsus) and injectable formulations.
– Patent expiries (notably for Novo Nordisk’s drugs in 2026) will enable generic
Application Scenarios:
– Pharmaceutical intervention for obesity management in adults.
– Adjunct therapy for type 2 diabetes patients needing weight control.
– Long-term weight management strategies in clinical care.
– Prescription for patients with obesity and/or high risk of metabolic syndrome.
Pros:
– Clinically proven significant weight reduction (up to 15% over 68 weeks with
– Promote satiety and reduce appetite, supporting sustainable weight loss.
– Potentially improve diabetes management alongside obesity treatment.
– Future affordability and accessibility expected to improve due to generics and
Cons:
– Current cost is high (e.g., ₹12,900 per month for domestic supply; imported
– Affordability remains a barrier for most of the Indian population without
– Presence of gray market and counterfeit drugs due to cost and supply issues
– Efficacy, availability, and cost-effectiveness after patent expiry will depend
OneSource Expands GLP-1 Drug-Device Capacity as Demand Soars
Product Details:
OneSource Specialty Pharma provides contract development and manufacturing (CDMO) services focused on drug-device combinations, with specialization in GLP-1 cartridge filling, assembly, fill-finish, and large-scale soft gelatine capsule production.
Technical Parameters:
– Expertise in cartridge filling and full assembly of GLP-1 drug-device
– Tripled manufacturing capacity for soft gelatine capsules
– Significant investment in expanding drug-device and cartridge assembly capacity
Application Scenarios:
– Manufacturing of GLP-1 based drugs for diabetes and obesity treatment
– Production of generic injectable pharmaceuticals requiring drug-device
– Serving pharmaceutical clients in America, Europe, the Middle East, Africa, and
Pros:
– Increased capacity to meet the growing global demand for GLP-1 treatments
– Comprehensive capabilities in drug-device combinations, including cartridge
– Significant investment capital ensures further expansion and scalability of
Cons:
– Recent and rapid expansion may present operational or integration risks
– Heavy reliance on continued market growth for GLP-1 drugs
Glenmark launches biosimilar of anti-diabetic drug Liraglutide in India
Product Details:
Glenmark has launched a biosimilar version of the anti-diabetic drug Liraglutide in India.
Technical Parameters:
– Biosimilar formulation of Liraglutide
– Intended for diabetes treatment
Application Scenarios:
– Treatment of diabetes, particularly Type 2 diabetes
– Use in patients requiring GLP-1 receptor agonist therapy as part of diabetic
Pros:
– Provides an alternative to branded Liraglutide for cost-effective diabetes
– Supports increased accessibility of GLP-1 therapy in India
Cons:
– As a biosimilar, clinical experience and physician/patient trust may initially
– Potential uncertainty about long-term efficacy and safety compared to the
India to make drugs for diabetes, obesity under PLI by 2026 … – IBEF
Product Details:
India will begin producing drugs for diabetes and obesity, including key innovative medicines like semaglutide, under the Production Linked Incentive (PLI) scheme by 2026.
Technical Parameters:
– Production of innovative drugs such as semaglutide
– Manufacturing supported by the PLI scheme aimed at boosting domestic
Application Scenarios:
– Treatment of diabetes
– Management of obesity
Pros:
– Boosts India’s position as a global supplier of crucial medications
– Potentially lowers costs and increases accessibility for patients in India and
– Reduces dependency on drug imports
– Drives manufacturing innovation in the pharmaceutical sector
Cons:
– Manufacturing will only start by 2026, causing a delay in immediate availability
– Potential challenges in meeting international quality standards initially
Comparison Table
| Company | Product Details | Pros | Cons | Website |
|---|---|---|---|---|
| Indian Pharmaceutical Companies: GLP-1 Drug Manufacturing | GLP-1 drugs (glucagon-like peptide-1 agonists) manufactured by Indian | Expected reduction in drug prices due to competition and generic manufacturing | Market entry and sales for obesity applications subject to regulatory approval | resources.pharmalinkage.com |
| India to make Ozempic-like drugs for diabetes, obesity under PLI by … | Indian pharmaceutical companies will manufacture GLP-1 receptor agonist | Promotes both improved blood glucose control and clinically significant weight | Current global supply is constrained, leading to shortages and circulation of | www.business-standard.com |
| Glenmark is the first to launch Biosimilar of Popular Anti-Diabetic … | Glenmark has launched the biosimilar of Liraglutide, a popular anti-diabetic | First biosimilar of Liraglutide launched in India, potentially increasing | Potential skepticism around efficacy or safety compared to the original branded | www.prnewswire.com |
| Novo Nordisk India launches world’s first and only GLP-1 RA, Oral … | Novo Nordisk India has launched Rybelsus®, the world’s first and only oral | Oral formulation offers increased convenience and improved patient compliance | As a new oral medication, some patients may experience gastrointestinal side | medgatetoday.com |
| Eli Lilly launches once-a-week diabetes drug in India | Eli Lilly has launched a once-a-week diabetes drug in India. | Reduced frequency of injections compared to daily treatment Potential for | Requires injection (not oral) Specific efficacy and safety profile details not | economictimes.indiatimes.com |
| India To Manufacture Popular Diabetes And Obesity Drugs From 2026 Under … | India will begin manufacturing popular diabetes and obesity drugs domestically | Domestic manufacturing may lead to improved self-reliance in critical | Manufacturing is scheduled to begin only in 2026, causing potential delays in | knnindia.co.in |
| GLP-1 Therapies Transforming Obesity Treatment in India | GLP-1 receptor agonists (including semaglutide, liraglutide, and upcoming | Clinically proven significant weight reduction (up to 15% over 68 weeks with | Current cost is high (e.g., ₹12,900 per month for domestic supply; imported | www.aranca.com |
| OneSource Expands GLP-1 Drug-Device Capacity as Demand Soars | OneSource Specialty Pharma provides contract development and manufacturing | Increased capacity to meet the growing global demand for GLP-1 treatments Compre | Recent and rapid expansion may present operational or integration risks Heavy | www.thepharmanavigator.com |
| Glenmark launches biosimilar of anti-diabetic drug Liraglutide in India | Glenmark has launched a biosimilar version of the anti-diabetic drug | Provides an alternative to branded Liraglutide for cost-effective diabetes | As a biosimilar, clinical experience and physician/patient trust may initially | health.economictimes.indiatimes.com |
| India to make drugs for diabetes, obesity under PLI by 2026 … – IBEF | India will begin producing drugs for diabetes and obesity, including key | Boosts India’s position as a global supplier of crucial medications Potentially | Manufacturing will only start by 2026, causing a delay in immediate | www.ibef.org |
Frequently Asked Questions (FAQs)
How can I verify if a GLP-1 manufacturer in India is certified and reputable?
Check if the manufacturer has certifications like GMP (Good Manufacturing Practices), WHO-GMP, or US FDA approval. Request documentation directly, visit their facility if possible, and look for customer reviews or third-party audits to ensure reliability and compliance with international standards.
What should I look for when comparing GLP-1 manufacturers in India?
Focus on product quality, manufacturing capacity, regulatory compliance, R&D capabilities, and client testimonials. Ask about their track record in exporting, batch consistency, and willingness to provide quality certifications for their products.
Are Indian GLP-1 manufacturers able to accommodate custom formulation requests?
Many reputable Indian manufacturers offer custom formulation services and can modify dosage forms, concentrations, or packaging as per client requirements. Always confirm this during initial discussions and ask about minimum order quantities and lead times.
How important is visiting the factory before finalizing a supplier?
A site visit is highly recommended as it allows you to assess the facility’s hygiene, technology, and production processes firsthand. If a visit isn’t possible, request a live virtual tour or comprehensive third-party audit report for transparency.
What are common contract terms to clarify with Indian GLP-1 suppliers?
Discuss pricing, minimum order quantity, delivery timelines, payment terms, liability for quality issues, and intellectual property protection. Clear agreements on these points help avoid misunderstandings and ensure a smooth partnership.
